Traders should monitor the FDA decision on March 20, 2026, as approval could significantly expand IMCIVREE’s market and drive revenue growth. Positive EU and Japanese regulatory momentum adds further upside potential.
RYTM drugs
RYTM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $94.94entry
- T+1 · 9mo ago −5.67%α −4.75% · $89.56
- T+5 · 8mo ago −2.04%α −0.84% · $93.00
- T+20 · 8mo ago −18.63%α −10.69% · $77.25
- T+60 · 6mo ago −5.39%α −14.72% · $89.82
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rhythm Pharmaceuticals announced additional positive 52-week data from its Phase 3 TRANSCEND trial showing a -18.8% placebo-adjusted BMI reduction for setmelanotide in patients with acquired hypothalamic obesity (HO), supporting its supplemental New Drug Application (sNDA) currently under FDA review with a PDUFA decision date of March 20, 2026. The data include Japanese and supplemental cohorts, strengthening the clinical package ahead of regulatory decisions in the U.S., EU, and planned submission in Japan.
Key Facts
- Setmelanotide showed a -18.8% placebo-adjusted difference in BMI reduction at 52 weeks in 142 patients with acquired hypothalamic obesity.
- Primary endpoint: -16.4% mean BMI reduction from baseline in setmelanotide group vs. +2.4% in placebo (p<0.0001).
- In patients aged 12+, setmelanotide reduced weekly average most hunger score by 2.5 points vs. 1.3 in placebo (p=0.0015).
- FDA PDUFA goal date for sNDA is March 20, 2026; final data package to be submitted March 2, 2026.
- EMA review ongoing with CHMP opinion expected in Q2 2026 and potential EU approval in H2 2026.
- Plans to submit full data to Japan’s PMDA for marketing authorization.
Financial Impact
Potential expansion of IMCIVREE's addressable market by up to 38,000 patients across the U.S., EU, and Japan if approved for acquired HO.
Risk Factors
- FDA may not approve the sNDA despite positive data.
- Commercial uptake in acquired HO may be limited by diagnosis challenges and small patient population.
- Safety concerns such as depression, hypersensitivity, and skin hyperpigmentation remain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3246959 |
Track record
26 reports on RYTM
9 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers